Get started
Author

Michael Mauro

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines
2003 · Paul La Rosée, Kara Johnson, et al. · Blood · 100
STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
2001 · Michael Mauro, Michael O'Dwyer, et al. · Cancer Chemotherapy and Pharmacology · 39
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
2012 · Richard A. van Etten, Michael Mauro, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
257: Validation of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after matched unrelated donor SCT
2007 · T. Kovacsovics, B. Hayes-Lattin, et al. · Transplantation and Cellular Therapy · 3
Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003
2025 · Michael Mauro, Lisa Rein, et al. · Blood · 1
PDF
318: Busulfan, Fludarabine and Total Body Irradiation Followed by Allogeneic Peripheral Blood Stem Cell Transplantation is an Effective Treatment for Hematologic Malignancies with Acceptable Toxicity in a Higher-Risk Population
2008 · G. Meyers, A. Dunn, et al. · Transplantation and Cellular Therapy · 1
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)
2026 · Michael Mauro, Jerald Radich, et al. · Future Oncology
PDF
Modernising diagnosis and treatment of Chronic Myeloid Leukaemia for improved patient outcomes in a resource-limited setting: Experiences from Ghana’s premier teaching hospital
2026 · Amma Anima Benneh-Akwasi Kuma, Michael Mauro · Journal of Interventional Epidemiology and Public Health
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)
2026 · Mauro, Michael, Radich, Jerald, et al. · Figshare
Changes in disease responses after discontinution of tyrosine kinase inhibitors (TKI) for pregnancy in established chronic myeloid leukaemia (CML): Evidence for the basis of advice for women of child-bearing age
2025 · Jenny Chan, Harry Robertson, et al. · Blood
PDF
State of CML Treatments
2013 · Michael Mauro, Jerald P. Radich
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. - eScholarship
2013 · Richard A. Van Etten, Michael Mauro, et al.
The Evolving Role of Outcomes and End Points in Evaluating Therapy for Hematologic Malignancies: Value-Driven Benefit Design and Utilization Management Strategies
2011 · Michael Mauro
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
2010 · Michael Mauro
Long-Term Benefits of Imatinib in Patients with Chronic Myeloid Leukemia
2006 · Tariq Mughal, Michael Mauro, et al. · Clinical Leukemia
Works count: 15
Citation count: 153
H-index: 3
I10-index: 2
Year
Topic
Type